Molecular Formula | C15H13NO2 |
Molar Mass | 239.27 |
Melting Point | 200.0 to 204.0 °C |
Water Solubility | Soluble in 1eq. NaOH (30 mM), ethanol (100 mM), DMSO (100 mM), DMF (~30 mg/ml), and water (0.5 mg/ml at 25°C). |
Solubility | DMSO: soluble10mg/mL, clear |
Appearance | powder |
Color | white to beige |
Storage Condition | -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month. |
In vitro study | DPN has a 70-fold ERα relative binding affinity selectivity, and it is a full ERα agonist with a 78-fold ERα potency selectivity (EC 50 =0.85 nM for ERβ; EC 50 =66 nM for ERα). DPN (10 nM) prevents morphological alterations from Aβ 1-42 (10 μM)-induced toxicity in cultured cortical neurons. DPN (0.1-100 nM) decreases ROS levels in a non-dose response manner. DPN (0.1-100 nM) significantly reduces Aβ 1-42 -stimulated expression of Bax in a non-dose dependent manner. DPN (0.1-100 nM) reduces activated IL-1 levels induced by Aβ 1-42 treatment on cultured cortical neurons. DPN (0.1-100 nM) suppresses the Aβ 1-42 -upregulated phosphorylation of JNK and p38. |
Risk Codes | R36 - Irritating to the eyes R50 - Very Toxic to aquatic organisms |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. |
UN IDs | UN 3077 9 / PGIII |
WGK Germany | 3 |
RTECS | UG0900000 |
Hazard Class | 9 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.179 ml | 20.897 ml | 41.794 ml |
5 mM | 0.836 ml | 4.179 ml | 8.359 ml |
10 mM | 0.418 ml | 2.09 ml | 4.179 ml |
5 mM | 0.084 ml | 0.418 ml | 0.836 ml |
biological activity | DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor beta selective ligand, its EC50 value was 0.85 nM. DPN has neuroprotective effects in many neurological diseases. |
Animal Model: | Adult Sprague-Dawley female rats (220-250 g), ovariectomized animal models |
Dosage: | 10 μg/rat |
Administration: | Subcutaneous injections, daily, for 11 days |
Result: | Increased swimming and decreased immobility in the FST. |